| Septerna Therapeutics (NASDAQ: SEPN) | G protein-coupled receptor (GPCR); Therapeutics | J.P. Morgan Securities, Cantor Fitzgerald, TD Securities, Wells Fargo Securities | 10/24/2024 | $18.00 | $288 million | $18 |
| Baylis Medical (TSX: BAY) | Medical devices; Cardiac electrophysiology | RBC Capital Markets, National Bank Financial, Stifel GMP | 10/09/2024 | CAD$15.00 | CAD$94.5 million | CAD$14 – 16 |
| Tranzyme Pharma (NASDAQ: TZYM) | Small molecule therapeutics; Cardiometabolic diseases | J.P. Morgan Securities, SVB Securities, Wedbush Securities | 09/26/2024 | $16.00 | $30 million | $14 – $16 |
| Spero Therapeutics (NASDAQ: SPRO) | Anti-infectives; Bacterial infections | J.P. Morgan Securities, Jefferies, Stifel GMP | 08/29/2024 | $14.00 | $55.75 million | $13 – $15 |
| Atturo Health (NASDAQ: ATTU) | Digital therapeutics; Pain management | Roth Capital Partners, Aegis Capital, Maxim Group | 08/15/2024 | $10.00 | $20 million | $9 – $11 |
| UroGen Pharma (NASDAQ: URGN) | Urology-focused therapeutics | Goldman Sachs & Co., J.P. Morgan Securities, Piper Sandler | 07/25/2024 | $17.00 | $200 million | $15 – $18 |
| Alder Biopharmaceuticals (NASDAQ: ALDR) | Monoclonal antibodies; Migraine treatment | Credit Suisse, Barclays, BofA Securities | 06/20/2024 | $21.00 | $220 million | $19 – $22 |
| NeuroMetrix (NASDAQ: NURO) | Neurological diagnostics and therapeutics | Stifel GMP, Canaccord Genuity, Lake Street Capital Markets | 05/10/2024 | $13.00 | $40 million | $12 – $14 |
| Inozyme Pharma (NASDAQ: INZY) | Rare disease therapeutics; Enzyme replacement | J.P. Morgan Securities, Cowen, Evercore ISI | 04/17/2024 | $19.00 | $150 million | $17 – $20 |
| Viaskin Therapeutics (NASDAQ: VSKN) | Allergy immunotherapy; Peanut allergy | Leerink Partners, Wells Fargo Securities, William Blair | 03/30/2024 | $12.00 | $65 million | $11 – $13 |